Vascular Biology |
From the Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Correspondence to G.P. van Nieuw Amerongen, PhD, VU university Medical Center, Laboratory for Physiology, Boechorstraat 7, 1081BT, Amsterdam, The Netherlands. E-mail nieuwamerongen{at}vumc.nl
Objective— Rho kinase mediates vascular leakage caused by many vasoactive agents including thrombin. Enhanced Rho kinase activity induces endothelial barrier dysfunction by a contractile mechanism via inactivation of Myosin Phosphatase (MP). Here, we investigated the contribution of basal Rho kinase activity to the regulation of endothelial barrier integrity.
Methods and Results— Using a phospho-specific antibody against the myosin phosphatase targeting subunit (Thr696–MYPT1) as a marker for Rho kinase activity, basal endothelial Rho kinase activity was observed at cell-cell contact sites, in vitro and in situ. Thrombin enhanced MYPT phosphorylation at F-actin stress fibers. Inhibition of basal Rho kinase activity for 24 hours or depletion of Rho kinase (ROCK-I and -II) by siRNA disrupted endothelial barrier integrity, opposite to the previously observed protection from the thrombin-enhanced endothelial permeability. This barrier dysfunction could not be explained by changes in RhoA, Rac1, eNOS, or apoptosis. Remarkably, basal Rho kinase activity was essential for proper expression of the adhesion molecule VE-cadherin.
Conclusions— Rho kinase has opposing activities in regulation of endothelial barrier function: (1) an intrinsic barrier-protective activity at the cell margins, and (2) an induced barrier-disruptive activity at contractile F-actin stress fibers. These findings may have implications for long-term antivascular leak therapy.
A well-known effect of activation of Rho kinase by vasoactive agents is disruption of endothelial barrier integrity. Here, we provide evidence for a role of basal Rho kinase activity in regulating proper expression of the junctional adhesion molecule VE-cadherin, opposite to the barrier-disruptive effects of Rho kinase.
Key Words: endothelial cells MYPT1 myosin phosphatase cytoskeleton
This article has been cited by other articles:
![]() |
B. Schulz, J. Pruessmeyer, T. Maretzky, A. Ludwig, C. P. Blobel, P. Saftig, and K. Reiss ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial Cadherin Circ. Res., May 23, 2008; 102(10): 1192 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Townsend, J. L. Wrana, G. E. Davis, and J. V. Barnett Transforming Growth Factor-{beta}-stimulated Endocardial Cell Transformation Is Dependent on Par6c Regulation of RhoA J. Biol. Chem., May 16, 2008; 283(20): 13834 - 13841. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. van Nieuw Amerongen, R. J. P. Musters, E. C. Eringa, P. Sipkema, and V. W. M. van Hinsbergh Thrombin-induced endothelial barrier disruption in intact microvessels: role of RhoA/Rho kinase-myosin phosphatase axis Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1234 - C1241. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |